Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have been assigned a consensus recommendation of “Moderate Buy” from the sixteen research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, fourteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $199.5333.

A number of equities analysts have recently commented on PVLA shares. Mizuho raised their price objective on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Chardan Capital restated a “buy” rating and issued a $240.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st. BTIG Research raised their price objective on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. HC Wainwright raised their price objective on Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Finally, Stephens restated an “overweight” rating and issued a $220.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st.

Insider Activity

In other news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the sale, the chief operating officer owned 2,154 shares in the company, valued at approximately $238,512.42. This trade represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.20% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

A number of large investors have recently modified their holdings of the stock. First Light Asset Management LLC grew its stake in shares of Palvella Therapeutics by 38.3% in the first quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock valued at $122,251,000 after buying an additional 271,617 shares in the last quarter. Suvretta Capital Management LLC grew its stake in shares of Palvella Therapeutics by 8.5% in the fourth quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock valued at $93,408,000 after buying an additional 70,000 shares in the last quarter. Jennison Associates LLC grew its stake in shares of Palvella Therapeutics by 65.3% in the first quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock valued at $79,852,000 after buying an additional 253,128 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Palvella Therapeutics by 13.3% in the fourth quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock valued at $58,680,000 after buying an additional 65,960 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Palvella Therapeutics by 206.3% in the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock valued at $44,010,000 after buying an additional 283,211 shares in the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Price Performance

Palvella Therapeutics stock opened at $129.84 on Thursday. The stock’s 50-day moving average is $118.25 and its 200-day moving average is $109.69. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -31.14 and a beta of -0.15. Palvella Therapeutics has a 12 month low of $20.35 and a 12 month high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). Research analysts anticipate that Palvella Therapeutics will post -5.26 EPS for the current year.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.